We were able to confirm our in vitro findings by inducing myogenic differentiation and potently suppressing tumor growth in an aRMS PDX model with an in vivo combination of RAF (regorafenib or dabrafenib) and MEK (trametinib) targeting at clinically relevant doses. Here, MAP2K7 is linked to neoplasm.